Burden of chemotherapy-induced myelosuppression among patients with ES-SCLC in US community oncology settings

• Published in: Future oncology (London, England) Vol. 18; no. 35; pp. 3881 - 3894
• Main Authors: Goldschmidt, Jerome, Monnette, Alisha, Shi, Ping, Venkatasetty, Divea, Lopez-Gonzalez, Lorena, Huang, Huan
• Format: Journal Article
• Language: English
• Published: England 01.11.2022
• Subjects: Antineoplastic Agents - adverse effects; Humans; Lung Neoplasms - drug therapy; Small Cell Lung Carcinoma - drug therapy; extensive-stage small-cell lung cancer; health care costs; myelosuppression; health care resource utilization; treatment patterns; supportive care interventions
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2022-0754

To describe the burden of chemotherapy-induced myelosuppression among chemotherapy-treated patients with extensive-stage small-cell lung cancer (ES-SCLC). Occurrence of grade ≥3 myelosuppressive hematological adverse events (HAEs), treatment patterns and healthcare resource utilization (HCRU) after chemotherapy initiation were evaluated using data from The US Oncology Network and Non-network clinics (1/1/2015-12/31/2020). Among patients with laboratory values (Network: N = 1,374/1,574; Non-network: N = 661/959), over half-experienced grade ≥3 HAEs after chemotherapy initiation (Network = 56.6%; Non-network = 64.1%), and approximately one-third had grade ≥3 HAEs in at least two lineages (Network = 33.0%; Non-network = 31.3%). Patients with grade ≥3 HAEs had greater dose reductions, treatment delays and HCRU than those without. Myelosuppression is a burden to patients with ES-SCLC treated with chemotherapy and the healthcare system.